WINNIPEG, MB--(Marketwired - December 07, 2016) - 3D Signatures Inc. (TSX VENTURE: DXD) (the "Company" or "3DS") presented the preliminary results of an important collaborative initiative between the Company and the Institut Universitaire de Cardiologie et de Pneumologie De Quebec (IUCPQ) exploring the possibility of identifying a biological marker to distinguish between two deadly forms of lung cancer, multiple synchronous lung adenocarcinoma (AC) and metastatic lung AC, which is a significant unmet clinical need in the management of patients with multiple lung lesions. In every blinded patient sample the Company analyzed, 3DS technology was able to distinguish between the two respective types of deadly lung cancer. The poster is being presented at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC) taking place in Vienna, Austria from December 4 to 7, 2016.
3DS technology was used to differentiate blindly between 19 lung cancer patients, 10 with synchronous lung AC and 9 with metastatic AC. Patient tissue samples were provided by the Biobank at IUCPQ and the experimental study design was the result of a fruitful collaboration between Dr. Philippe Joubert, Thoracic Pathologist and Scientist at IUCPQ, Dr. Sabine Mai, co-founder of 3DS and Dr. Oumar Samassekou, VP Clinical Programs at 3DS. The acquisition of 3D telomere images and analysis was performed in the Company's reference lab using 3DS' proprietary software platform, TeloView™, while the experiments, data analysis and interpretation was performed in a multi-centre collaboration between Dr. Sabine Mai, Dr Philippe Joubert and Nathalie Bastien, a postdoctoral fellow at IUCPQ.
Principal Investigator, Dr. Philippe Joubert, and Company Director and Chair of 3DS' Clinical and Scientific Advisory Board, Dr. Sabine Mai stated:
This important research would not be possible without the support of IUCPQ. These preliminary results suggest that 3DS has a promising molecular imaging technology that has the potential to improve the management of AC patients who present with multiple lung lesions.
Currently, there is no molecular tool to aid clinicians in distinguishing between patients with synchronous lung AC and patients with metastatic lung AC. While only patients with synchronous lung cancer are likely to benefit from surgical resection, it is important for the treating physician to accurately identify these two groups of patients in order to optimize their management. 3DS' platform technology has the potential to help clincians personalize treatments for a significant portion of lung cancer patients -- and potentially improve outcomes in one of the most deadly forms of lung cancer. Additional studies are being planned between IUCPQ and 3DS to further validate these results and move 3DS' novel biomarker closer to commercialization.
About the IUCPQ
Since its creation in 1918, the Institut Universitaire De Cardiologie et de Pneumologie de Quebec has stood on equal footing with leading North American establishments for ultra-specialized care. Specializing in the health of persons with cardiopulmonary diseases, the Institute is renowned and recognized internationally as a leader. What distinguishes the Institute is its expertise and innovative practices, its focus on research and teaching, and its technological advances. The Institute is where specialized expertise and the sharing of knowledge come together in an ongoing quest for excellence. The close and continuing synergy between clinical activities, research, teaching and the evaluation of health technologies and interventions ensures a care approach guided by best practices and forms the cornerstone of the Institute's mission.
About the World Lung Cancer Conference
The IASLC World Conference on Lung Cancer (WCLC) is the world's largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries to discuss the latest developments in thoracic malignancy research. Attendees include surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses and allied health professionals and patients.
3DS (TSX VENTURE: DXD) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis chromosomal signatures. The technology is well developed and supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease. Depending on the desired application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company's new website at http://www.3dsignatures.com.
This news release includes forward-looking statements that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. In particular, the Company's statements that it expects to benefit greatly from its association with the individuals named in this news release is forward-looking information. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company's existing products or the Company's ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company's financial condition; the Company's ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.